Top Markets
Coin of the day
TCR2 Therapeutics Inc. TCR2 Therapeutics Inc.

TCR2 Therapeutics Inc.

TCRR
Ранг среди акций #27038
TCR2 Therapeutics Inc. is a clinical-stage immunotherapy firm focused on... TCR2 Therapeutics Inc. is a clinical-stage immunotherapy firm focused on developing cutting-edge T cell receptor (TCR) therapies for cancer patients. The company's lead investigational treatment, gavo-cel, is a unique mono TCR Fusion Construct T cell (TRuC-T cell) designed to target mesothelin-positive solid tumors. This therapy is currently being evaluated in Phase I/II clinical trials for non-small cell lung cancer (NSCLC), ovarian cancer, malignant pleural/peritoneal mesothelioma, and cholangiocarcinoma. Furthermore, TCR2 Therapeutics has concluded preclinical development for TC-510, another TRuC-T cell specifically engineered to target mesothelin on solid tumors. They are also advancing TC-520, a CD70-targeting TRuC-T cell designed with fratricide resistance for treating renal cell carcinoma. Founded in 2015, the company, formerly known as TCR2, Inc. until its name change in November 2016, is headquartered in Cambridge, Massachusetts.
Цена акции
$1.48
Последняя синхронизация: 2023-05-31
Рыночная капитализация
$35.54M
Изменение (1 день)
-5.73%
Изменение (1 год)
0.00%
Страна
US
Торговля TCR2 Therapeutics Inc. (TCRR)

Категория

История цены акций TCR2 Therapeutics Inc. (TCRR)
Наивысшая цена закрытия: $1.83 2023-05-01

Наименьшая цена закрытия: $16.51 2019-02-01
История цены акций TCR2 Therapeutics Inc. с 2019 по 2026
Годовая динамика цены акций
Год Результативность
2023 73.43%
2022 -78.52%
2021 -83.60%
2020 79.84%
2019 0.00%
Цена акций похожих компаний или конкурентов
Компания Цена акций Изменение 1г% Страна
$552.07 39.99%
US
$168.77 527.63%
US
$1.03K 56.22%
NL
$120.74 -14.98%
AU
$758.23 6.53%
CH